• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Preclinical safety assessment of MV-s-NAP, a novel oncolytic measles virus strain armed with an < em > H < /em > < em > . < /em > < em > pylori < /em > immunostimulatory bacterial transgene
In this study, we utilized a measles-infection-permissive mouse model (transgenic IFNAR KO-CD46Ge) to evaluate the biodistribution and safety of MV-s-NAP. The primary objective was to identify potential toxic side effects and confirm the safety of the proposed clinical doses of MV-s-NAP prior to a phase I clinical trial of intratumoral administration of MV-s-NAP in patients with MBC. Both subcutaneous delivery (corresponding to the clinical trial intratumoral administration route) and intravenous (worst case scenario) delivery of MV-s-NAP were well tolerated: no significant clinical, laboratory or histologic toxicity was o...
Source: Clinical Genitourinary Cancer - September 12, 2022 Category: Cancer & Oncology Authors: Kimberly B Viker Michael B Steele Ianko D Iankov Susanna C Concilio Arun Ammayappan Brad Bolon Nathan J Jenks Matthew P Goetz Eleni Panagioti Mark J Federspiel Minetta C Liu Kah Whye Peng Evanthia Galanis Source Type: research

Oncolytic measles vaccines encoding PD-1 and PD-L1 checkpoint blocking antibodies to increase tumor-specific T  cell memory
Mol Ther Oncolytics. 2021 Nov 29;24:43-58. doi: 10.1016/j.omto.2021.11.020. eCollection 2022 Mar 17.ABSTRACTPD-1/PD-L1 checkpoint blockade has achieved unprecedented success in cancer immunotherapy. Nevertheless, many immune-excluded tumors are resistant to therapy. Combination with oncolytic virotherapy may overcome resistance by inducing acute inflammation, immune cell recruitment, and remodeling of the tumor immune environment. Here, we assessed the combination of oncolytic measles vaccine (MV) vectors and PD-1/PD-L1 blockade. In the MC38cea model of measles virus oncolysis, MV combined with anti-PD-1 and MV vectors enc...
Source: Cancer Control - January 3, 2022 Category: Cancer & Oncology Authors: R ūta Veinalde Gemma Pidelaserra-Mart í Coline Moulin Lara M Jeworowski Linda K üther Christian J Buchholz Dirk J äger Guy Ungerechts Christine E Engeland Source Type: research

A recombinant Chinese measles virus vaccine strain rMV-Hu191 inhibits human colorectal cancer growth through inducing autophagy and apoptosis regulating by PI3K/AKT pathway
In this study, the antitumor effects of rMV-Hu191 were evaluated in CRC both in vitro and in vivo. From our data, rMV-Hu191 induced remarkably caspase-dependent apoptosis and complete autophagy in vitro. In mice bearing CRC xenografts, tumor volume was remarkably suppressed and median survival was prolonged significantly with intratumoral treatment of rMV-Hu191. To gain further insight into the relationship of rMV-Hu191-induced apoptosis and autophagy, we utilized Rapa and shATG7 to regulate autophagy. Our data suggested that autophagy was served as a protective role in rMV-Hu191-induced apoptosis in CRC. PI3K/AKT signalin...
Source: Translational Oncology - April 13, 2021 Category: Cancer & Oncology Authors: Chu-di Zhang Yi-Long Wang Dong-Ming Zhou Meng-Ying Zhu Yao Lv Xiao-Qiang Hao Chu-Fan Qu Yi Chen Wei-Zhong Gu Ben-Qing Wu Pei-Chun Chen Zheng-Yan Zhao Source Type: research